Jeil Pharmaceutical said Monday that it has launched Duglow Tab, a combination drug  that blends dapagliflozin with pioglitazone,  to treat type-2 diabetes.

Duglow Tab combines the dapagliflozin, SGLT-2 inhibitor, and pioglitazone, thiazolidinedione (TZD).

SGLT-2 inhibitors lower blood sugar by inhibiting glucose reabsorption by the kidneys, while thiazolidinediones lower blood sugar by making muscle tissue more sensitive to insulin, which helps glucose be absorbed into the muscle.

Dapagliflozin promotes sugar excretion in the urine, and pioglitazone improves insulin resistance, offering a valuable option for long-term glycemic control in type 2 diabetes patients, according to Jeil.

In addition, the combo drug is expected to mitigate side effects such as weight changes and edema, thereby preventing major complications associated with type 2 diabetes, including stroke, myocardial infarction, cerebrovascular disease, and non-alcoholic fatty liver, the company said.

Jeil highlighted that the phase 3 clinical trial results from earlier this year demonstrated significant improvements in homeostatic model assessment of insulin resistance (HOMA-IR), triglyceride (TG), and high-density lipoproteins cholesterol (HDL-C) compared to the control group.

"As active glycemic control is being emphasized to prevent complications, which is the ultimate goal of diabetes treatment, Duglow Tab will be a new treatment option for patients with diabetes," a Jeil official said. "We hope that Duglow Tab will help improve the quality of life of patients, including effective glycemic control and prevention of cardiovascular diseases."